Clinical Trial Update: Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line Treatment [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating AZD6094 (Volitinib) in combination with docetaxel for second-line treatment in advanced gastric adenocarcinoma with MET overexpressio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma

Drugs mentioned

• AZD6094 (Volitinib) (volitinib)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Samsung Medical Center | Conditions: Advanced Gastric Adenocarcinoma | Phase 2 | Status: COMPLETED